Copyright
©The Author(s) 2021.
World J Gastrointest Endosc. Apr 16, 2021; 13(4): 97-110
Published online Apr 16, 2021. doi: 10.4253/wjge.v13.i4.97
Published online Apr 16, 2021. doi: 10.4253/wjge.v13.i4.97
Figure 1 Study flow diagram.
Allocation of patients into the “Low dose sedation” group (n = 63154) and “High dose sedation” group (n = 307819). Exclusion of patients based on sedation type/dose, incomplete data, and age (n = 285421). Low dose sedation parameters: Fentanyl ≤ 50 µg or meperidine ≤ 50 mg +/- midazolam ≤ 2 mg. High dose sedation parameters: Fentanyl ≥ 200 µg ormeperidine ≥ 150 mg +/- midazolam ≥ 6 mg +/- diphenhydramine (any dose). Sedation parameters excluded: Fentanyl > 50 µg to < 200 µg, meperidine > 50 mg to < 150 mg, and midazolam > 2 mg to < 6 mg. LD: Low dose; HD: High dose; EGD: Esophagogastroduodenoscopy.
- Citation: Passi M, Rahman F, Gurram S, Kumar S, Koh C. Identifying who best tolerates moderate sedation: Results from a national database of gastrointestinal endoscopic outcomes. World J Gastrointest Endosc 2021; 13(4): 97-110
- URL: https://www.wjgnet.com/1948-5190/full/v13/i4/97.htm
- DOI: https://dx.doi.org/10.4253/wjge.v13.i4.97